Sean Lim

Title: Innovations in Cancer Therapy by Inventor Sean Lim

Introduction

Sean Lim is a notable inventor based in Southampton, GB. He has made significant contributions to the field of cancer therapy, holding a total of 3 patents. His work focuses on innovative methods for treating B-cell related diseases and cancer, showcasing his commitment to advancing medical science.

Latest Patents

One of Sean Lim's latest patents involves a method for the treatment or prevention of B-cell related diseases. This method includes the administration of a binding molecule that targets B-cells, promoting their destruction, alongside an immunostimulatory agent that activates effector lymphocytes such as NK and T cells. Additionally, he has developed an anti-CD27 binding agent intended for use in combination therapy with an anti-CD20 binding agent for treating B-cell related diseases.

Another significant patent addresses cancer treatment. This invention describes a method that utilizes a cancer-cell-depleting binding agent to target and kill cancer cells, paired with an immunostimulatory agent to enhance NK and T-cell activation. The combination of an anti-CD27 binding agent with a cancer-cell-depleting binding agent is also highlighted for its potential in cancer therapy.

Career Highlights

Sean Lim is affiliated with the University of Southampton, where he conducts his research and development in the field of cancer therapies. His innovative approaches have positioned him as a key figure in the ongoing battle against cancer and related diseases.

Collaborations

Sean Lim collaborates with esteemed colleagues such as Mark Steven Cragg and Martin John Glennie. Their combined expertise contributes to the advancement of research in cancer treatment and immunotherapy.

Conclusion

Sean Lim's work exemplifies the intersection of innovation and medical research, particularly in the realm of cancer therapy. His patents reflect a dedication to improving treatment options for patients, making a significant impact in the field.